Korean Diabetes J.  2009 Apr;33(2):134-142. 10.4093/kdj.2009.33.2.134.

Risk Factors for Early Development of Macrovascular Complications in Korean Type 2 Diabetes

• Lee HR
• Yu JM
• Choi MG
• Yoo HJ
• Hong EG

• KMID: 2298070
• DOI: http://doi.org/10.4093/kdj.2009.33.2.134

Abstract

BACKGROUND
The average duration of diabetes and predictive factors of macrovascular complications in Korean diabetic patients remain to be elucidated. This study examines the average duration of diabetes up to the onset of macrovascular complications and clinically important factors of early development of these complications in Korean type 2 diabetic patients. METHODS: Clinical characteristics in type 2 diabetics with (n = 121) and without macrovascular complications (n = 115) were analyzed. In addition, early onset (< or = 5 years, n = 54) and late onset groups (> 5 years, n = 67) were compared, as were the clinical characteristics between male and female patients in the macrovascular complications group. RESULTS: The average duration of diabetes was 8.7 +/- 7.8 years in the macrovascular complications group. Average age, systolic and diastolic blood pressures and smoking history were all higher in the macrovascular complications group than the control group. However, HbA1c levels and prevalence of microvascular complications were higher in the controls. Average age was lower in the early onset group and many more patients of that group had a smoking history. In the analysis based on sex, marcrovascular complications developed earlier in male patients. In addition, the prevalence of family history of diabetes was higher in males and 77.8% of male patients had a smoking history (female: 3.4%). CONCLUSION: Our study confirms that older age, high blood pressure and smoking history are major risk factors for the development of macrovascular complications. Moreover, a smoking history in males can be both risk and predictive factors for earlier development of macrovascular complications in Korean type 2 diabetic patients. We also found that several clinical characteristics including age, family history of diabetes, hypertension and smoking history, vary between the sexes, and these findings can provide useful indices for the prevention of macrovascular complications.

Keyword

Diabetes complications; Risk factors; Type 2 diabetes mellitus

MeSH Terms

Diabetes Complications
Diabetes Mellitus, Type 2
Female
Humans
Hypertension
Male
Prevalence
Risk Factors
Smoke
Smoking
Smoke

Figure

• 

  Fig. 1 Prevalence of diabetic microvascular complications in the macrovascular complications group and the control group. Cx, Complications. *P < 0.05.

• 

  Fig. 2 Prevalence of diabetic microvascular complications in early onset and late onset groups of macrovascular complications. *P < 0.05.

• 

  Fig. 3 Prevalence of diabetic microvascular complications in male and female patients in the macrovascular complications group.

Reference

1. Stancoven A, McGuire DK. Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. Am J Cardiol. 2007. 99:5H–11H.

2. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med. 2005. 118:939–947.

3. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000. 102:1014–1019.

4. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cariol. 1996. 77:1017–1020.

5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993. 16:434–444.

6. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996. 124:136–145.

7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359:1577–1589.

8. Diaetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005. 353:2643–2653.

9. Ryu JS, Lee KU, Kim YT, Shong YK, Kim GS, Lee MH. The prevalence of various complications in relation to age and duration of diabetes mellitus. J Korean Diabetes Assoc. 1992. 16:145–150.

10. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E. Incedence of coronary heart disease in ty pe 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007. 30:1241–1247.

11. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006. 49:1761–1769.

12. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: 1 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996. 124:136–145.

13. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003. 348:383–393.

14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.

15. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C. VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complications. 2006. 20:75–80.

16. Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patient with type 2 diabetes mellitus. Mayo Clin Proc. 2001. 76:707–712.

17. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004. 27:201–207.

18. Coppell K, Williams S, Anderson K, Lamb C, Mann J. Characteristics and cardiovascular risk of new cases of type 2 diabetes in Otago, New Zealand, 1998-2004. Diabetes Res Clin Pract. 2008. 82:396–401.

19. Pineda J, Marín F, Roldán V, Valencia J, Marco P, Sogorb F. Premature myocardial infarction: clinical profile and angiographic findings. Int J Cardiol. 2008. 126:127–129.

20. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004. 27:2898–2904.

21. Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, MacMahon S. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in he Asia-Pacific region. Diabetes Care. 2003. 26:360–366.